10-Q: Xencor Q2 Revenue Soars, Pipeline Advances

Xencor, Inc. reported significantly increased revenue for the second quarter and first half of 2025, driven by milestone payments and royalties, while advancing multiple clinical-stage antibody therapeutics.

Summary

• Revenue for the three months ended June 30, 2025, increased to $43.6 million from $23.9 million in the same period of 2024, a 82.4% increase.
• Revenue for the six months ended June 30, 2025, increased to $76.3 million from $39.9 million in the same period of 2024, a 91.2% increase.
• Net loss for the three months ended June 30, 2025, improved to $(30.8) million, compared to $(67.3) million in the prior year period.
• Net loss for the six months ended June 30, 2025, improved to $(79.2) million, compared to $(140.8) million in the prior year period.
• Cash, cash equivalents, and marketable debt securities totaled $663.8 million as of June 30, 2025.
• Research and development expenses for the six months ended June 30, 2025, were $120.2 million, a slight increase from $118.4 million in the prior year period.
• General and administrative expenses for the six months ended June 30, 2025, were $32.5 million, a slight increase from $31.5 million in the prior year period.
• Net cash used in operating activities for the six months ended June 30, 2025, significantly improved to $(52.6) million from $(124.2) million in the prior year period.
• Received a $25.0 million milestone payment from Incyte in Q3 2025 following FDA approval of Monjuvi for relapsed or refractory follicular lymphoma.
• Received a $12.5 million milestone payment from Incyte in Q2 2025 for FDA acceptance of a supplemental biologics license application for Monjuvi.
• Received a $2.0 million milestone payment from Vir Bio in Q2 2025 for the initiation of a Phase 3 study for tobevibart.
• Advanced multiple clinical programs, including XmAb819 (ENPP3 x CD3) with initial anti-tumor activity, XmAb942 (Xtend TL1A) with positive Phase 1 interim results, and Plamotamab (CD20 x CD3) with regulatory authorization for a Phase 1b/2a study in rheumatoid arthritis.
• Identified material weaknesses in internal control over financial reporting related to accounting for future royalty sales and tax legislation evaluation, with remediation plans underway.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a significant reduction in net loss, driven by successful milestone achievements and royalties. Pipeline programs are advancing with positive early data and clear next steps. However, it remains a clinical-stage company with ongoing losses, and the identified material weaknesses in internal controls and an active patent lawsuit introduce elements of risk and uncertainty.

Positives

• Significant increase in revenue for both the three and six months ended June 30, 2025, driven by milestone payments and royalties.
• Substantial improvement in net loss and operating loss for both quarterly and six-month periods compared to the prior year.
• Reduced net cash used in operating activities, indicating improved operational efficiency or increased cash inflows from collaborations.
• Multiple clinical programs are advancing, with positive early-stage data and progression to later phases (e.g., XmAb819, XmAb942, Plamotamab).
• FDA approval of Monjuvi for relapsed or refractory follicular lymphoma triggered a $25.0 million milestone payment, demonstrating successful partnership and regulatory progress.
• XmAb942 showed good tolerability and an extended half-life (greater than 71 days) in Phase 1, supporting a potential 12-week dosing interval.
• Plamotamab demonstrated favorable tolerability and comparable preliminary efficacy to a competitor molecule in hematologic cancers, supporting its evaluation in autoimmune diseases.

Negatives

• Continued to incur significant net losses, with a net loss of $(79.2) million for the six months ended June 30, 2025.
• Total assets decreased to $879.4 million as of June 30, 2025, from $951.9 million at December 31, 2024.
• Total stockholders' equity decreased to $620.4 million as of June 30, 2025, from $677.6 million at December 31, 2024.
• Identified material weaknesses in internal control over financial reporting related to the accounting treatment of future royalty sales and evaluation of tax legislation.
• Asset impairment charges of $6.7 million for the six months ended June 30, 2025, related to pausing further development of certain programs.
• An ongoing patent infringement lawsuit initiated by Merus N.V. poses a legal and financial risk.

Risks

• The effects of inflation on financial condition, results of operations, cash flows, and performance.
• Ability to execute plans to research, develop, and commercialize product candidates.
• Success of ongoing and planned clinical trials is uncertain.
• Timing of and ability to obtain and maintain regulatory approvals for product candidates.
• Ability to identify additional products or product candidates with significant commercial potential.
• Ability to receive research funding and achieve anticipated milestones under collaborations.
• Partners' abilities to advance drug candidates into, and successfully complete, clinical trials.
• Ability to attract collaborators with development, regulatory, and commercialization expertise.
• Ability to protect intellectual property position, including the ongoing patent infringement lawsuit.
• Rate and degree of market acceptance and clinical utility of products.
• Costs of compliance and failure to comply with new and existing governmental regulations.
• Capabilities and strategy of suppliers and vendors, including key manufacturers of clinical drug supplies.
• Significant competition in the industry.
• Potential loss or retirement of key members of management.
• Failure to successfully execute growth strategy, including any delays in planned future growth.
• Failure to maintain effective internal controls, which led to restatement of financial statements and risk of additional material weaknesses.
• Ability to accurately estimate expenses, future revenues, capital requirements, and needs for additional financing.
• Unfavorable global economic or political conditions could adversely affect business, financial condition, or results of operations.
• Disruptions at the FDA and other government agencies caused by changing priorities or funding shortages could hinder product development and approval.

Future Outlook

Current financial resources are expected to fund operations into 2028. The company anticipates initiating a Phase 2b study of XmAb942 in ulcerative colitis in the third quarter of 2025 and a first-in-human study for XmAb657 in the second half of 2025. First-in-human studies for the XmAb TL1A x IL-23p19 bispecific antibody candidate are anticipated during 2026.

Management Comments

• The company leverages its protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties.
• Programs are advanced into clinical-stage development to determine which to progress to later-stage development, partner, or discontinue.
• The approach to protein design includes engineering Fc domains, which are constant and interchangeable among antibodies, to provide innovative approaches to treating disease and clinical benefits.

Industry Context

The company operates in the highly competitive and rapidly changing biopharmaceutical industry, focusing on engineered antibody therapeutics for cancer and autoimmune diseases. Its strategy of leveraging proprietary XmAb Fc domain technology and forming strategic partnerships aligns with industry trends of specialized drug development and collaborative models to share development costs and risks. The progress of its bispecific antibody candidates, such as T-cell engagers and co-stimulatory antibodies, reflects a broader industry shift towards more targeted and potent immunotherapies.

Comparison to Industry Standards

• Plamotamab's preliminary efficacy data from its Phase 1 study in hematologic cancers showed favorable tolerability and comparable results when cross-compared to studies of a competitor molecule within the same class, suggesting competitive potential.

Corporate Governance

Legal Proceedings

• The company is a party to a patent infringement action initiated by Merus N.V. in the District of Delaware, alleging infringement of U.S. Patent Nos. 9,944,695, 9,358,286, and 11,926,859 related to common light chain and heterodimeric antibodies.
• Merus seeks a judgment of patent infringement, an injunction, damages, a declaration of willful infringement, and a finding that the case is exceptional.
• The company filed a motion to dismiss the complaint on October 10, 2024, arguing that accused activities are covered by the 35 U.S.C. 271(e)(1) safe harbor.
• The company filed for inter partes review of Merus U.S. Patent Nos. 9,358,286 and 11,926,859 before the U.S. Patent and Trademark Appeal Board on February 11, 2025, seeking a finding that certain claims are unpatentable.
• The company believes it has strong defenses, including invalidity and/or non-infringement, but there is no guarantee of prevailing.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue and reduced losses, but potential dilution from future capital raises and ongoing legal risks.
• Employees: Continued investment in R&D programs and a replenished equity incentive plan may positively impact employee morale and retention.
• Partners: Successful milestone achievements and regulatory approvals strengthen existing partnerships and may attract new collaborations.
• Patients: Advancement of clinical programs offers potential new therapeutic options for cancer and autoimmune diseases.

Next Steps

• Initiate a Phase 2b study of XmAb942 in ulcerative colitis (XENITH-UC Study) in the third quarter of 2025.
• Initiate a first-in-human study for XmAb657 during the second half of 2025.
• Anticipate initiating first-in-human studies for the XmAb TL1A x IL-23p19 bispecific antibody candidate during 2026.
• Continue dose escalation for XmAb819 in its Phase 1 study.
• Characterization of target dose levels for XmAb541 anticipated to begin during 2025.
• Data from the Phase 1 dose-escalation study of XmAb808 are expected to inform future development decisions.

Key Dates

Recommendation

While Xencor demonstrated strong financial improvements with significant revenue growth and reduced net losses, driven by successful milestone payments and royalties, it remains a clinical-stage company with no internally commercialized products. The pipeline shows promising advancements, but the inherent risks of drug development, coupled with identified material weaknesses in internal controls and an ongoing patent infringement lawsuit, warrant a cautious approach. The company's liquidity position is strong, projected to fund operations into 2028, which provides stability. However, the long path to profitability and the need for continued R&D investment suggest a 'hold' recommendation, advising investors to monitor the progress of key clinical trials and the resolution of internal control and legal issues before considering further investment.

Keywords

Biotechnology, Antibody Therapeutics, Oncology, Autoimmune Diseases, XmAb, Clinical Trials, SEC Filing, Biopharma, Drug Development, Xencor, Milestone Payments, Royalties, Patent Infringement